Synthorx Inc., a La Jolla, Calif.-based biotechnology company using synthetic biology to discover and develop novel protein therapeutics, completed a $63m Series C financing.
The round was led by OrbiMed and joined by new investors, Medicxi and Osage University Partners, and existing investors, Avalon Ventures, RA Capital Management, and Correlation Ventures. In addition, Peter Thompson, M.D., private equity partner at OrbiMed, and Vickie Capps, an independent advisor with extensive financial and audit experience, will join the Synthorx board of directors.
The proceeds of the financing will be used to advance the company’s pipeline of Synthorin™ cytokines, including an IL-2 tuned specifically for activity on certain immune cells.
Led by Laura Shawver, Ph.D., president, CEO, and director, Synthorx uses expanded genetic alphabet technology based on synthetic biology to discover and develop novel protein therapeutics. The company’s expanded genetic alphabet platform has the ability to drive the site-specific incorporation of multiple synthetic amino acids into proteins thereby tuning receptor specificity important for improving efficacy and safety.